RET and cancer: A retrospective analysis of a pan-cancer cohort of 7517 patients treated with multi-TKIs plus 96 patients treated with RET-Is (pralsetinib, selpercatinib) showed that 15 patients developed CE (12 patients chylothorax, 5 patients CA, 5 both).